

Jurisdiction Specific Medicare Part B Filgrastim Products

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Neupogen	filgrastim
Nivestym	filgrastim-aafi
Nypozi	filgrastim-txid
Releuko	filgrastim-ayow
Zarxio	filgrastim-sndz

Covered Uses

The indications below are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

- Patients with cancer receiving myelosuppressive chemotherapy and/or immunotherapy
- Patients with acute myeloid leukemia receiving induction or consolidation chemotherapy
- Patients with cancer receiving bone marrow transplantation
- Patients undergoing autologous peripheral blood progenitor cell collection and therapy
- Patients with severe chronic neutropenia (congenital, cyclic, or idiopathic)
- Patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic syndrome of acute radiation syndrome)
- Adjunctive treatment of neutropenia in certain conditions
- Acute lymphocytic leukemia (ALL)
- Hairy cell leukemia
- Myelodysplastic syndromes (MDS) with severe neutropenia or recurrent infection
- Dose dense therapy for adjuvant treatment of breast cancer or other malignancies

Reference number(s)
4490-A

- Drug-induced (non-chemotherapy) neutropenia
- Glycogen storage disease type 1b
- Neutropenia associated with human immunodeficiency virus (HIV) infection and antiretroviral therapy
- Radiation therapy in the absence of chemotherapy
- After hematopoietic progenitor stem cell transplant (HPCT/HSCT) to promote reconstitution
- After hematopoietic progenitor stem cell transplant (HPCT/HSCT) when engraftment is delayed or has failed
- Mobilization of progenitor cells as an adjunct to peripheral blood/hematopoietic stem cell transplant (PBSCT/PHSCT)
- Alternate or adjunct to donor leukocyte infusions (DLI) after allogeneic hematopoietic stem cell transplant

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in this criteria should be accompanied by supporting evidence from Medicare approved compendia.

Exclusions

Coverage will not be provided for members with any of the following exclusions:

- Administration of filgrastim to increase chemotherapy dose intensity except as noted below
- Continuous use of filgrastim for myelodysplastic syndrome or Felty's syndrome without infections
- Chemosensitization of myeloid leukemias
- Continued use if no response is seen within 28-42 days
- Administration in members with chronic aplastic anemia

Coverage Criteria

Prevention of Febrile Neutropenia in Cancer Patients Receiving Myelosuppressive Chemotherapy and/or Immunotherapy¹⁻⁷

Authorization of 6 months may be granted for prevention of febrile neutropenia when the chemotherapeutic agents are covered by Medicare and any of the following criteria are met:

- Filgrastim will be used for primary prophylaxis in a member whose risk of febrile neutropenia is 20% or greater based on the chemotherapy regimen
- Filgrastim will be used for primary prophylaxis in a member whose risk of febrile neutropenia is greater than or equal to 10% and less than 20% based on the chemotherapy regimen and at least one of the following risk factors for febrile neutropenia are present:
 - Age greater than 65 years

Filgrastim products MedB Jurisdiction J (AL, GA, TN) and M (NC, SC, VA, WV) 4490-A P2025.docx © 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Reference number(s)
4490-A

- Poor performance status
- Previous episodes of febrile neutropenia
- History of previous chemotherapy or radiation therapy
- After completion of combined chemoradiotherapy
- Bone marrow involvement by tumor producing cytopenias
- Preexisting neutropenia
- Poor nutritional status
- Poor renal function
- Liver dysfunction (i.e., elevated bilirubin)
- Presence of open wounds or active infections
- Recent surgery (within the past 12 weeks)
- Advanced cancer
- Other serious comorbidities
- Filgrastim will be used as secondary prophylaxis when both of the following conditions are met:
 - The member has documented febrile neutropenia from a prior chemotherapy cycle (for which primary prophylaxis was not received)
 - A reduction in dosage of the chemotherapeutic agent or delay in treatment may compromise disease-free or overall survival or treatment outcome

Adjunctive Treatment of Neutropenia^{1,2}

Authorization of 6 months may be granted for adjunctive treatment of neutropenia when any of the conditions below are present:

- Expected prolonged (greater than 10 days) and profound (less than $0.1 \times 10^9/L$) neutropenia
- Age greater than 65 years
- Uncontrolled primary disease
- Pneumonia
- Hypotension and multiorgan dysfunction (sepsis syndrome)
- Invasive fungal infection
- Hospitalization at the time of the development of fever

Acute Myeloid Leukemia¹⁻⁷

Authorization of 6 months may be granted to reduce the time to neutrophil recovery and the duration of fever following induction or consolidation chemotherapy treatment of members with acute myeloid leukemia.

Bone Marrow Transplantation¹⁻⁷

Authorization of 6 months may be granted to reduce the duration of neutropenia and neutropenia-related clinical sequelae (e.g., febrile neutropenia) in members with non-myeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation.

Filgrastim products MedB Jurisdiction J (AL, GA, TN) and M (NC, SC, VA, WV) 4490-A P2025.docx © 2025 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of pharmaceutical manufacturers that are not affiliated with CVS Caremark.

Other Indications¹⁻⁷

Authorization of 6 months may be granted for treatment of any of the following conditions:

- Mobilization of autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- Acute exposure to myelosuppressive doses of radiation
- After completion of the first few days of initial induction chemotherapy or for first post-remission course of chemotherapy for the treatment of acute lymphocytic leukemia (ALL)
- Adult members with AML shortly after the completion of induction or repeat induction chemotherapy, or after the completion of consolidation therapy for AML
- Treatment of severe neutropenia in individuals with hairy cell leukemia
- Myelodysplastic syndrome when either of the following criteria is met:
 - Absolute neutrophil count (ANC) less than or equal to 500/mm³
 - Member is experiencing recurrent infection
- Dose dense chemotherapy (treatment given more frequently, such as every two weeks instead of every three weeks) for adjuvant treatment of breast cancer or other malignancies for which dose dense chemotherapy is an accepted treatment option
- Chronic administration to reduce the incidence and duration of sequelae (e.g., fever, infections, oropharyngeal ulcers) in symptomatic individuals with congenital neutropenia, cyclic neutropenia or idiopathic neutropenia
- Treatment of (non-chemotherapy) drug-induced neutropenia
- Treatment of low neutrophil counts in members with glycogen storage disease type 1b
- Treatment for neutropenia associated with human immunodeficiency virus (HIV) infection and antiretroviral therapy
- Member receiving radiation therapy in the absence of chemotherapy if prolonged delays due to neutropenia are expected
- After hematopoietic progenitor stem cell transplant (HPCT/HSCT) for any of the following conditions:
 - To promote myeloid reconstitution
 - When engraftment is delayed or has failed
 - Mobilization of progenitor cells into peripheral blood for collection by leukapheresis, as an adjunct to peripheral blood/hematopoietic stem cell transplantation (PBSCT/PHSCT)
 - As an alternate or adjunct to donor leukocyte infusions (DLI) in members with leukemic relapse after an allogenic hematopoietic stem cell transplant

Dosage and Administration

Services performed for excessive frequency are not medically necessary. Frequency is considered excessive when services are performed more frequently than generally accepted by peers and the reason for additional services is not justified by documentation. Filgrastim will be covered when administered

Reference number(s)
4490-A

under direct supervision in the office setting. When administered by the member or caregiver, the drug will be considered self-administered and not payable.

References

1. White Cell Colony Stimulating Factors LCD (L37176) Version R16. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed June 26, 2025.
2. Billing and Coding: White Cell Colony Stimulating Factors (A56748) Version R14. Available at: <https://www.cms.gov/medicare-coverage-database/indexes/national-and-local-indexes.aspx>. Accessed June 26, 2025.
3. Neupogen [package insert]. Thousand Oaks, CA: Amgen Inc.; June 2025.
4. Nivestym [package insert]. Lake Forest, IL: Hospira Inc.; February 2024.
5. Nypozi [package insert]. San Diego, CA: Tanvex BioPharma USA, Inc.; June 2024.
6. Releuko [package insert]. Piscataway, NJ: Kashiv Biosciences, LLC; April 2025.
7. Zarxio [package insert]. Princeton, NJ: Sandoz, Inc.; October 2024.